SIG-1451: A Topical Anti-Inflammatory New Chemical Entity for Atopic Dermatitis
April 2017
in “
Journal of Investigative Dermatology
”
SIG-1451 atopic dermatitis non-steroidal anti-inflammatory drug pro-inflammatory cytokines IL-4 IL-6 TSLP PBMCs endothelial cells NHEKS S. aureus AN2728 TPA edema oxazolone delayed type hypersensitivity DTH Investigational New Drug IND AD non-steroidal anti-inflammatory cytokines Staphylococcus aureus acute inflammation hypersensitivity
Studysummary In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document from May 1, 2017, reports on the effectiveness of SIG-1451, a new non-steroidal anti-inflammatory drug for atopic dermatitis (AD). The study showed that SIG-1451 inhibits pro-inflammatory cytokines such as IL-4 in human PBMCs, IL-6 in endothelial cells, and TSLP in NHEKS induced by S. aureus, which are key in AD pathogenesis. The in vitro potency of SIG-1451 was comparable or superior to existing AD treatments, with the exception of IL-4 induction by AN2728. Additionally, in vivo models demonstrated SIG-1451's anti-inflammatory properties, reducing edema in both the TPA acute inflammation ear model and the oxazolone mouse model for delayed type hypersensitivity (DTH). The study concludes with the potential of SIG-1451 as a drug candidate for AD, with preclinical safety evaluations in progress for an Investigational New Drug (IND) submission.
